A New Way to Treat Triple-Negative Breast Cancer
RNase H2 is a novel therapeutic target in triple negative breast cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11116849
This research explores a new approach to treat triple-negative breast cancer by targeting a specific enzyme called RNase H2.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11116849 on ClinicalTrials.gov |
What this research studies
Triple-negative breast cancer cells grow very quickly and have unstable DNA, leading to high levels of stress during DNA replication. We want to understand how these cancer cells manage this stress, as it could reveal new ways to stop their growth. Our work has shown that an enzyme called RNase H2 helps these cancer cells survive this stress, and it is often found in high amounts in triple-negative breast tumors. By blocking RNase H2, we've seen that cancer cells are specifically killed, while healthy cells are not harmed. This suggests that targeting RNase H2 could be a promising new treatment strategy.
Who could benefit from this research
Good fit: This foundational research focuses on understanding cancer biology, so it does not directly involve patient participation at this stage, but future clinical trials would seek patients with triple-negative breast cancer.
Not a fit: Patients with other types of cancer or those without triple-negative breast cancer would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this research could lead to a new and effective treatment option for patients with triple-negative breast cancer.
How similar studies have performed: This approach of targeting RNase H2 for triple-negative breast cancer is novel, though other studies have explored targeting replication stress in cancer.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIN, SHIAW-YIH — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: LIN, SHIAW-YIH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer Cell, Breast Cancer Prevention, Breast Cancer Treatment, Breast Cancer cell line